Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S. Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not marketing Compounding platform value, 18 clinically validated products targeted: Each new "18" product retroactively strengthens every existing one - the portfolio becomes more valuable with every addition CHICAGO, IL / ACCESS Newswire / April 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. introduction of the "18 Series" - a premium nutraceutical platform designed to meet growing consumer demand for clinically validated health solutions. 1. The 18 Series - Overview Cosmos Health Inc. is executing a disciplined, science-first strategy to build the what we believe to be most credible clinical supplement portfolio in the United States.